Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Short, K Detweiler, Rajkumar, SV, Larson, D, Buadi, F, Hayman, S, Dispenzieri, A, Gertz, M, Kumar, S, Mikhael, J, Roy, V, Kyle, RA, Lacy, MQ
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736849/
https://ncbi.nlm.nih.gov/pubmed/21350560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.29
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia